Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND II: Asacol 4.8 g/day vs 2.4 g/day in Moderately Active Ulcerative Colitis
NCT00073021Phase 3Completed
- Sponsor
- Warner Chilcott
- Start
- Sep 2000
- Primary completion
- Sep 2003
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of Salcrozine in ulcerative colitis (UC), sponsored by Warner Chilcott. Primary endpoint: Percentage of Treatment Success Patients at 6 weeks. Started Sep 2000; status: completed.
02
Drugs
Salcrozine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00073021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073021.